Healthcare Global Enterprises DuPont analysis

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.87×0.89×0.87×0.61×0.39×
0.17×0.11×0.32×0.43×0.33×
8.5%8.7%7.9%8.1%8.0%
0.68×0.68×0.71×0.76×0.75×
2.78×2.78×3.58×3.13×2.66×
2.4%1.7%5.6%5.1%2.1%
1.2%1.2%5.1%5.7%3.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

HCG₹591.45

Healthcare Global Enterprises Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPFORTISRAINBOWJLHLCORONAMARKSANSMETROPOLISPARKHOSPSMcap ₹8,511 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.390.610.870.890.87
Interest Burden (Pretax/EBIT) ×0.330.430.320.110.17
EBIT Margin %7.988.127.928.718.51
Asset Turnover ×0.750.760.710.680.68
Financial Leverage (Assets/Equity) ×2.663.133.582.782.78
ROE (5-step product, year-end total equity) %2.085.145.581.692.39
ROE (owners' profit / average owners' equity) %3.395.715.081.221.22
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.